ASND (Ascendis Pharma A/S Ordinary Share) stock: $236.72, $15.55B market cap, $723.9M cash, $15.65B EV, $16.84B fully diluted market cap. Next expected readout: Jun-27. Lead program: Palopegteriparatide (Hypoparathyroidism), Phase 3. Data from Fully Diluted's biotech stocks database.
Pipeline assets
YORVIPATH
Approved · Active Modality: prodrug of PTH (1-34) (TransCon; once-daily)
Aliases palopegteriparatide, TransCon PTH
Target PTH receptor (PTH 1-34 prodrug)
Partnerships Teijin Limited (Japan: commercially available since November 2025); VISEN Pharmaceuticals (Greater China); SKYTROFA/VISEN collaboration
Indications- Hypoparathyroidism in adults (Approved)
Status note Approved by FDA August 9, 2024 and authorized by EC November 2023 for treatment of adults with hypoparathyroidism. Commercially available in the U.S. since December 2024; also authorized by other regulatory agencies globally.
SKYTROFA
Approved · Active Modality: long-acting prodrug of human growth hormone (TransCon; once-weekly)
Aliases lonapegsomatropin-tcgd, TransCon hGH
Target growth hormone receptor
Partnerships VISEN Pharmaceuticals (Greater China; authorized in China January 2026); Teijin Limited (Japan, endocrinology rare diseases)
Indications- Growth hormone deficiency (pediatric patients one year and older) (Approved)
- Growth hormone deficiency (adults) (Approved)
- Turner syndrome (children) (Stage not disclosed)
Status note FDA approved August 25, 2021 for pediatric GHD and July 25, 2025 for adult GHD; EC marketing authorization January 2022 for children and adolescents 3-18 with GHD. TransCon hGH also in development for children with Turner syndrome and other established daily growth hormone indications.
TransCon CNP
Phase 3 · Active Modality: prodrug of C-type natriuretic peptide (TransCon)
Aliases navepegritide, TransCon CNP
Target NPR-B (CNP receptor)
Partnerships Teijin Limited (Japan); VISEN Pharmaceuticals (Greater China); combination of TransCon CNP and TransCon hGH under investigation
Indications- Achondroplasia (children) (Phase 3)
- Achondroplasia (infants, children, adolescents; alone and in combination with TransCon hGH) (Stage not disclosed)
- Hypochondroplasia (children; alone and in combination with TransCon hGH) (Stage not disclosed)
Status note Currently under regulatory review in the United States and European Union for the treatment of children with achondroplasia (NDA pending; company responded to the FDA in September 2025 regarding a Citizen Petition). Also being investigated for achondroplasia in infants, children and adolescents and for hypochondroplasia, alone and in combination with TransCon hGH.
TransCon IL-2
Phase 1 · Active Modality: long-acting IL-2 variant prodrug (TransCon; systemic delivery)
Aliases onvapegleukin alfa, TransCon IL-2 b/g
Target IL-2 beta/gamma
Indications- Locally advanced or metastatic solid tumors (Phase 1)
Status note IL-Believe Phase 1/2 trial in locally advanced or metastatic solid tumors, alone or in combination, including a cohort combining with chemotherapy.
TransCon TLR7/8 Agonist
Phase 1 · Active Modality: long-acting prodrug of resiquimod (TransCon; intratumoral delivery)
Aliases TransCon TLR7/8
Target Toll-like receptors 7 and 8
Indications- Solid tumors (intratumoral) (Phase 1)
Status note Long-acting prodrug of resiquimod. In Q4 2024 the company closed enrollment in the BelieveIT-201 trial and dose expansion cohorts in the transcendIT-101 and IL-Believe trials to prioritize efforts on TransCon IL-2.
Per-asset detail extracted from the 20-F filed 2026-02-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.